19 completed, 4 not yet recruiting, 3 recruiting, 2 active not recruiting. 28 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 28 | Completed 19, Not yet recruiting 4, Recruiting 3, Active not recruiting 2 |
| Phase 2 | 6 | Completed 2, Not yet recruiting 2, Active not recruiting 1, Recruiting 1 |
Follow Single Person: new trials by email Literature Review of Single Person trials Research Report on Single Person
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Venlafaxine Combined With Education and Behavioral Intervention for Bladder Pain Syndrome Venlafaxine oral tablet combined with Education and Behavioral Modification Program (EBMP), Education and Behavioral Modification Program (EBMP) only - Bladder Pain Syndrome, Chronic Pelvic Nociplastic Pain | Phase 1 | Not yet recruiting | Beijing Tiantan Hospital | 140 | 2026-12-31 | 2026-07-13 |
| Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery Cannabidiol (CBD) only, Placebo only, Delta-9-tetrahydrocannabinol (THC) only - PTSD, Post Traumatic Stress Disorder | Phase 1 / Phase 2 | Not yet recruiting | Leslie Lundahl | 280 | 2026-09-01 | 2026-08-26 |
| Effectiveness of Epigallocatechin-3-Gallate (Green Tea Extract) as Adjunctive Locally Delivered Nanotherapeutic in the Treatment of Stage II Periodontitis Ten patients with stage II periodontitis will receive epigallocatechin-3-gallate (EGCG)-loaded chitosan nanoparticulate gel injected into the periodontal pockets, chitosan nanoparticulate gel (CTN gel), scaling and root planing (SRP) only. - Peridontitis | Phase 1 | Recruiting | Mansoura University | 30 | 2026-03-16 | 2026-08-10 |
| Compare Morphine and Dexmedetomidine as Adjuvants to Bupivacaine in Ultrasound-guided ACB for Postoperative Analgesia After Knee Surgeries Adductor Canal Block (ACB) Only - Postoperative Analgesia, Morphine and Dexmedetomidine | Phase 1 / Phase 2 | Not yet recruiting | Kafrelsheikh University | 15 | 2025-11-17 | 2025-11-20 |
| A Study of Single Dose of LP-003 in Adolescent Subjects LP-003 Dose 1 (Single), LP-003 Dose 2 (Single) - Allergic Diseases | Phase 1 / Phase 2 | Active not recruiting | Longbio Pharma | 6 | 2025-10-01 | 2026-02-17 |
| In Situ Injection of Anti-angiogenics in Patients With Brain Arteriovenous Malformations Not Eligible for Exclusion Treatment Single in situ intra-arterial injection of bevacizumab - Brain Arteriovenous Malformations | Phase 1 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 20 | 2025-10-01 | 2025-07-20 |
| Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) FLOT, FOLFOX, FOLFIRI - Gastroesophageal Adenocarcinoma | Phase 1 | Recruiting | University of California, Irvine | 20 | 2025-06-27 | 2026-03-10 |
| Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants Arm 1 - DehydraTECH-CBD alone, Arm 2 - DehydraTECH-semaglutide alone, Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide - Type2diabetes | Phase 1 | Completed | Lexaria Bioscience Corp. | 148 | 2024-12-04 | 2026-01-12 |
| Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer Gemcitabine and C3 (Metformin, Simvastatin, and Digoxin), C3 (Metformin, Simvastatin, and Digoxin) only - Pancreatic Cancer Metastatic | Phase 1 / Phase 2 | Recruiting | State University of New York - Downstate Medical Center | 25 | 2024-04-17 | 2026-08-03 |
| A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics IBI3002, Placebo - Healthy Participants, Asthma | Phase 1 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 52 | 2024-02-26 | 2025-11-21 |
| Study of Intravenous ZMA001 in Healthy Subjects Placebo Cohort 1 (1.5 mg/kg/dose) only, ZMA001 (BC-NKA-20008) - Pulmonary Arterial Hypertension PAH | Phase 1 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 40 | 2023-11-27 | 2026-11-09 |
| A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants LP-005 Dose 1 (Single), LP-005 Dose 2 (Single), LP-005 Dose 3 (Single) - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 1 | Completed | Longbio Pharma | 68 | 2023-11-23 | 2025-12-15 |
| Evaluation of Safety and Pharmacokinetics of Oral Controlled-ileal-release Nicotinic Acid (CIR-NA) Compared to Immediate-release Nicotinic Acid and Placebo in Healthy Subjects and Subjects With Prediabetes controlled-ileal-release nicotinic acid (SAD/ MAD/MD) single- and multiple-ascending dose (SAD/MAD) or multiple dose (MD), immediate-release nicotinic acid (SAD), Placebo controlled-ileal-release nicotinic acid (SAD/MAD) - Safety Issues, Pharmacokinetic | Phase 1 | Completed | University Hospital Schleswig-Holstein | 60 | 2022-12-19 | 2024-11-27 |
| Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Doses of XC243 After Single and Multiple Oral Administration in Healthy Volunteers. XC243 50 mg single, XC243 100 mg single, Placebo single - Healthy Volunteers | Phase 1 | Completed | PHARMENTERPRISES LLC | 38 | 2022-09-28 | 2023-11-18 |
| A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects LP-001 Dose 1 (Single), LP-001 Dose 2 (Single), LP-001 Dose 3 (Single) - Myelodysplastic Syndrome (MDS) | Phase 1 | Completed | Longbio Pharma | 68 | 2022-09-03 | 2025-12-15 |
| A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants LP-003 Dose 1 (Single), LP-003 Dose 2 (Single), LP-003 Dose 3 (Single) - Chronic Spontaneous Urticaria | Phase 1 | Completed | Longbio Pharma | 60 | 2022-07-13 | 2025-12-12 |
| CKD-506 Drug-Drug Interaction Study in Healthy Male Subjects Midazolam, CKD-506 - Drug Drug Interaction | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 17 | 2022-02-28 | 2022-08-25 |
| Recombinant Human Alkaline Phosphatase in Healthy Japanese Subjects single 1-hour IV infusion of 0.8 mg/kg recAP, single 1-hour IV infusion of 1.6 mg/kg recAP, single 1-hour IV infusion of 3.2 mg/kg recAP - Healthy | Phase 1 | Completed | AM-Pharma | 34 | 2021-05-07 | 2022-03-14 |
| Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW Truvada alone, Truvada plus Leuprolide 11.25mg intramuscular injection, Truvada plus Estradiol 1 mg - HIV, Prophylaxis | Phase 1 | Completed | Johns Hopkins University | 13 | 2021-03-01 | 2026-04-06 |
| Study to Assess Safety, Tolerability and Pharmacokinetics of XC7 (Which is Planned Use in the Treatment of COVID-19) in Healthy Volunteers XC7 100 mg single, XC7 200 mg single, Placebo single - Covid19, Healthy Volunteers | Phase 1 | Completed | NP Therapeutics | 16 | 2020-12-17 | 2021-09-22 |
Showing 20 of 28. Sign in to see all of them.
COVID-19 (2) · Anemia, Sickle Cell (1) · Asthma (1) · Carcinoma, Non-Small-Cell Lung (1) · Chronic Urticaria (1) · Coronavirus Infections (1) · Cystitis, Interstitial (1) · Hemoglobinuria, Paroxysmal (1) · Intracranial Arteriovenous Malformations (1) · Iron Overload (1) · Lecithin Cholesterol Acyltransferase Deficiency (1) · Lupus Erythematosus, Systemic (1) · Myelodysplastic Syndromes (1) · Pancreatic Neoplasms (1) · Prediabetic State (1)
Longbio Pharma (4) · AM-Pharma (1) · ApoPharma (1) · Assistance Publique - Hôpitaux de Paris (1) · Beijing Tiantan Hospital (1) · Chong Kun Dang Pharmaceutical (1) · Daewoong Pharmaceutical Co. LTD. (1) · Dizal Pharmaceuticals (1) · GlaxoSmithKline (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Israel Institute for Biological Research (IIBR) (1) · Johns Hopkins University (1) · Kafrelsheikh University (1) · Leslie Lundahl (1) · Lexaria Bioscience Corp. (1)
United States (8) · China (4) · Australia (3) · Germany (2) · Russia (2) · Belgium (1) · Canada (1) · Egypt (1) · France (1) · Israel (1) · Japan (1) · Netherlands (1) · South Africa (1)
Annelies Legters (1) · Clifford L Ferguson, MD (1) · Denis Soulieres, MD (1) · Farshid Dayyani, MD,PhD (1) · Felicia Browne, ScD (1) · Huan Zhou (1) · Jason M Elinoff, M.D. (1) · Maria Velinova,, MD, PhD (1) · Mark A Marzinke, PhD (1) · Mohan Preet, MD (1) · Royce Morrison (1) · Susanna Nikolaus, Prof. Dr. (1)
PMID 25318563, PMID 28441975, PMID 28887751, PMID 34870327, PMID 34981144, PMID 41106035
2023 (1), R01AI145675 (1)